About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5627 record(s)
Req # A-2025-001
All Briefing Documents related to a Ministerial appearance before the Standing Committee on Transport, Infrastructure and Communities on 19 November 2020.Organization: Canada Infrastructure Bank
May 2024
Req # A-2025-002
All internal correspondence from November 19, 2020 to April 4, 2024 regarding Lake Diefenbaker Irrigation Projects.Organization: Canada Infrastructure Bank
May 2024
Req # A-2024-007
Correspondence (emails and briefing notes) between the Chippewas of Georgina Island First Nation and the Canada Infrastructure Bank, regarding funding agreement discussions for the Georgina Island Fixed Link Project with the Canadian Infrastructure Bank from 2022-04-26 to 2023-09-01.Organization: Canada Infrastructure Bank
April 2024
Req # A-2025-003
Please provide all communications, including attachments, received with respect to the "recycling" or "reprocessing" or re-use of nuclear fuel waste (irradiated nuclear fuel, used fuel, spent fuel, CANDU fuel) for any purpose received between January 1, 2023, and April 19, 2024. Please include communications within the department and those received from other federal departments, Crown agencies, regulatory bodies and contracted entities, and any private sector entity or agent including but not limited to the Canadian Nuclear Society, Canadian Nuclear Association, CANDU Owners Group or others, and any non-governmental organization or educational institution or individual.Organization: Canada Infrastructure Bank
April 2024
Nothing to report this month
Organization: Canadian Museum of History
Req # A-2024-013
Pursuant to the Access to Information Act, R.S.C. 1985, c. A-1, I hereby request access to the following records: 1. A copy of the agreement(s) involving the Canada Infrastructure Bank (CIB), Macquarie Asset Management, Porter Aviation Holdings Inc., the Montreal Metropolitan Airport (YHU), and/or any related companies in relation to the investment project for the development of a new domestic airport terminal at the Montreal Metropolitan Airport (YHU). 2. A copy of any reports, plans, prospectuses, or similar documents related to the above-referenced investment project.Organization: Canada Infrastructure Bank
March 2024
Req # A-2016-000420
Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.Organization: Health Canada
March 2024
Req # A-2019-001464
All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of October 1, 2018 - end of March 2019.Organization: Health Canada
March 2024
Req # A-2019-001525
The Clinical Overview, Clinical Summary of Efficacy and Clinical Summary of Safety submitted to Health Canada as part of the Supplemental New Drug Submission (SNDS) (control number: 204690; decision date: 2018-03-29) in respect of TALTZ.Organization: Health Canada
March 2024
Req # A-2020-001374
For the period 2015 to April 19, 2021, and in relation to natural health product brand names containing the phrase “glucosamine sulfate” or “glucosamine sulphate”, with license holders named WN Pharmaceuticals Ltd, Natural Factors Nutritional Products Limited, or Jamieson Laboratories Inc., the following documents. All product licences, and the specifications to which the natural health product will comply. All applications for a product licence, correspondences with respect to those applications, and the attestations by the applicants that the product will be manufactured and distributed in accordance with good manufacturing practices. All testing done of the product, and correspondences made in relation to the testing of the product. All correspondences between the Minister and a licensee, manufacturer, importer or distributer to stop their sale of the product. All correspondences in relation to labelling and packaging of the product; and all complaints of non-compliance in respect of the product. For the period May 6, 2004 to April 19, 2021, all monographs of “glucosamine sulfate” and “glucosamine hydrochloride”Organization: Health Canada
March 2024